China Issues First Update to Medical Device Clinical Trial Guidelines in 12 Years

| Printer friendly version

The Chinese Food and Drug Administration (“CFDA”) recently announced its first update to the medical device clinical trial guidelines in 12 years.  The finalized revision to the 2004 Medical Device Clinical Studies Rules (“MDCSR”) is titled Good Clinical Practice for Medical Device (“Device GCP”) and becomes effective on June 1, 2016.  The Device GCP guidelines apply to medical device clinical studies performed for the purpose of obtaining regulatory approval.

The new Device GCP includes several major changes to the 2004 MDCSR, adding 11 new chapters and 96 articles.  The guidelines cover such topics as patient safety, clinical study protocols, retention and documentation of records and reports, device management, and additional sponsor and investigator responsibilities.

Overall, the changes reflect increased regulatory oversight by the CFDA, particularly in regards to patient safety and record-keeping practices.  A few changes are highlighted below.

Patient safety protections include enhanced sponsor monitoring requirements and additional requirements for patient informed consent.  The guidelines provide stricter sponsor monitoring requirements and strengthen the role of ethics committees in study design and monitoring.  The additional requirements for patient informed consent include the types of information that must be provided as well as acceptable methods for obtaining informed consent.

The guidelines also provide additional requirements for multicenter studies.  Under the revised Device GCP, the lead site principal investigator and ethics committee will be required to actively coordinate implementation of the study and ethics reviews for all study sites.

Record-keeping requirements have also been significantly heightened.  The new guidelines require that each study site maintain all data and records for at least ten years after the completion of the studies.  The study sponsors are also required to maintain additional copies of all study records while the device remains in use.  Study sponsors are further required to contact and register with the provincial CFDAs prior to commencement of the study.

Companies seeking to obtain regulatory approval for new medical devices in China are highly encouraged to review the revised Device GCP and update their practices.

 

Leave a Reply

By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.